Biotechnology
Page 1 • 10 itemsGain critical insights into global biotech markets. NovaPharmaNews delivers essential intelligence for pharma BD, investors & analysts.
Claruvis Pharmaceutical's Retoxin Becomes World's First Approved Recombinant Botulinum Toxin Type A in China
China's NMPA approves Retoxin, the world's first recombinant botulinum toxin type A, marking a technological breakthrough in aesthetic medicine treatments.
Samsung Bioepis Partners with ATLATL Innovation Center to Accelerate Asia-Pacific Biotech Development
Samsung Bioepis and ATLATL Innovation Center sign MoU to accelerate early-stage biotech innovation across Asia-Pacific region through open collaboration.
Akso Health Group Launches Brain-Computer Interface R&D Program Targeting Neurotechnology Market
Akso Health Group (NASDAQ: AHG) announces entry into brain-computer interface development, establishing R&D infrastructure for next-generation neurotechnology solutions.
Washington State Life Sciences Industry Leads National Growth for Fifth Consecutive Year, Contributing $24.4B to GDP
Washington's life sciences sector outpaces national growth for 5th year, contributing $24.4B to state GDP with third-largest AI specialist cluster in US.
Turbine Partners with Crown Bioscience to Advance AI-Powered Cancer Drug Discovery Using Organoid Technology
Turbine and Crown Bioscience announce strategic partnership combining AI virtual screening with organoid tumor models to accelerate oncology research and drug development.
Alamar Biosciences NASDAQ IPO: Precision Proteomics Company Debuts at $1.5B Valuation
Alamar Biosciences (NASDAQ:ALMR) successfully listed on NASDAQ at $17 per share, opening at $22.6 with $1.5B market cap in precision proteomics breakthrough.
Antengene Presents Three Novel Cancer Programs at AACR 2026: Next-Generation ADC and TCE Therapies Show Promise
Antengene Corporation unveiled three innovative cancer treatment programs at AACR 2026, featuring next-generation ADC and TCE technologies for oncology patients.
Atara Biotherapeutics Class Action Lawsuit Filed: ATRA Stockholders May Recover Investment Losses from May 2024-January 2026
Robbins LLP announces class action lawsuit for Atara Biotherapeutics (ATRA) investors who purchased securities between May 20, 2024 and January 9, 2026.
Sanyou AI-STAL 2.0 Reduces Antibody Discovery Time from Months to 14 Days in Drug Development Breakthrough
Sanyou's AI-STAL 2.0 platform revolutionizes drug discovery by reducing antibody development timelines from months to just 14 days, transforming pharmaceutical R&D.
Atelerix Partners with JH Health to Expand Non-Cryogenic Cell Preservation Technology in Middle East
Atelerix forms strategic partnership with JH Health Ltd to bring revolutionary hydrogel cell preservation technology to Saudi Arabia and Middle East markets.